Farudodstat

DB16049InvestigationalSmall molecule

Farudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia).

Mechanism: Pharmacologically active on Dihydroorotate dehydrogenase (quinone), mitochondrial
Curator reviewed
Formula / weight: C₁₉H₁₄F₂N₂O₃ · 356.329 g/mol (avg)
Also known as: 2-((3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino)nicotinic acid · 2-((3,5-DIFLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)-3-PYRIDINECARBOXYLIC ACID · 3-PYRIDINECARBOXYLIC ACID, 2-((3,5-DIFLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)-
Code names: ASLAN-003

Resolves to

Compound

Structure

InChIKeyOMPATGZMNFWVOH-UHFFFAOYSA-NSMILESCOC1=CC(=CC=C1)C1=CC(F)=C(NC2=C(C=CC=N2)C(O)=O)C(F)=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Farudodstat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.